For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
Nine scientists at IRB Barcelona form part of EMBO, an organisation that comprises more than 1,800 outstanding researchers from Europe and around the world specialised in molecular biology.
“This will allow me to strengthen interactions with other European researchers, as well as to stay abreast of new ideas, concepts and technologies,” says Aznar Benitah.
BIST has selected 12 winners, among them Guiomar Solanas, Jelena Urosevic and Lidia Mateo.
This programme recognises excellence in research and supports women scientists in their transition to leadership positions.
The study, published in The Journal of Cell Biology, focuses on the development of the sperm tail, the structure that enables sperm cells to swim and is therefore critical for male fertility.
Organizations of the industry, and associations connected to R+D+i express their support towards research, backing the petition of the Severo Ochoa and María de Maeztu alliance (SOMMa) which advocates in favour of the political class acting to clear the administrative problems currently affecting science in Spain.
SOMMa and the organizations supporting this initiative such as IRB Barcelona, represent close to 6,800 businesses, societies, centres and research units, which give employment to more than 500,000 people in Spain, and have an economic activity equivalent to 10,53 % of the gross domestic product.
Sergi Ferrer-Salat, president of the Board of Trustees of the Ferrer Research Foundation, highlighted that the work done by IRB Barcelona scientist, Manuel Serrano, is helping to further our understanding of the relation between ageing and cancer and identify approaches to manipulate this relation to our advantage.
IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.
Researchers at IRB Barcelona discover the mechanism that leads to a less harmful form of obesity that is associated with the number rather than volume of fat cells.
There are several types of obesity and some are more harmful than others.
The study has been published in the journal Nature Cell Biology.
The latest Meet Our Scientists series is devoted to Marta Vilaseca, manager of the Mass Spectrometry & Proteomics Core Facility at IRB Barcelona.
The video "Proteins caught in fraganti" presents her specialised field.
A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.